All In Biotech

Drug Trial Radar · NCT04577820

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva

Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 13, 2021

Primary completion

Mar 1, 2022

Study completion Oct 8, 2022

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP. The primary efficacy objective of the study is to assess the effect of garetosmab on Heterotopic ossification (HO) in Japanese adult patients with FOP, as determined by the number of new heterotopic bone lesions identified by computed tomography (CT).

Conditions

  • Fibrodyplasia Ossificans Progressiva (FOP)
  • Heterotopic Ossification (HO)

Interventions

  • garetosmabDrug

    Repeated doses administered intravenously (IV) every four weeks (Q4W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse event (TEAEs)Time frame: Through week 28
  2. Number of new HO lesions as assessed by CTTime frame: At week 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.